Denali CMO restates 204,402-share insider holding

Denali Therapeutics Inc. executive Peter Scott Chin filed an amended Form 3 to restate his reported common stock holdings.

Rhea-AI Filing Summary

Denali Therapeutics Inc. executive Peter Scott Chin filed an amended Form 3 to restate his reported common stock holdings. The filing updates Table I to show direct ownership of 204,402 shares of Denali Therapeutics common stock. It does not report any new stock purchases or sales.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chin Peter Scott

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 204,402 shares (Direct)

Footnotes (1)

1. F1. This Form 3/A is being filed to restate the Reporting Person's Table I ownership.

Key Figures

Direct common shares held: 204,402 shares Insider filing type: Form 3/A Unknown transaction entries: 1 entry

3 metrics

Direct common shares held 204,402 shares Total common stock directly owned after restated Table I

Insider filing type Form 3/A Amended initial beneficial ownership report restating Table I

Unknown transaction entries 1 entry Recorded as holding with unknown transaction code

Key Terms

Form 3/A, Table I ownership, Chief Medical Officer, Common Stock

4 terms

Form 3/A regulatory

"This Form 3/A is being filed to restate the Reporting Person's Table I ownership."

An amended Form 3 (Form 3/A) is a corrected or updated disclosure filed with regulators that revises an insider’s initial report of their ownership in a public company — typically for officers, directors or large shareholders. Investors use it like a corrected inventory list: it clarifies who owns how many shares and whether earlier reports had errors, helping assess insider confidence, possible conflicts and the accuracy of ownership records that can affect stock valuation and trust.

Table I ownership regulatory

"This Form 3/A is being filed to restate the Reporting Person's Table I ownership."

Chief Medical Officer financial

"officer_title: "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Denali Therapeutics (DNLI) Chief Medical Officer report in this Form 3/A?

The Form 3/A shows that Chief Medical Officer Peter Scott Chin directly holds 204,402 shares of Denali Therapeutics common stock. The amendment is described as a restatement of the reporting person’s Table I ownership, clarifying his previously reported beneficial holdings.

Does the Denali Therapeutics (DNLI) Form 3/A show any new insider buying or selling?

The Form 3/A does not show any new insider purchases or sales. It records a single holding entry, with no buy or sell transactions, and simply restates Peter Scott Chin’s Table I common stock ownership at 204,402 directly held shares.

How many Denali Therapeutics (DNLI) shares does Peter Scott Chin hold after this Form 3/A?

After the restated ownership, Peter Scott Chin is shown holding 204,402 shares of Denali Therapeutics common stock. These shares are listed as direct ownership in Table I, reflecting his position as of the reported date in the amended filing.

What is the purpose of this amended Form 3/A for Denali Therapeutics (DNLI)?

The purpose is to restate the reporting person’s Table I ownership. The footnote explains that this Form 3/A is being filed specifically to correct and update Peter Scott Chin’s previously reported common stock holdings, without introducing new transactions.

What role does Peter Scott Chin hold at Denali Therapeutics (DNLI) in this filing?

In this filing, Peter Scott Chin is identified as an officer of Denali Therapeutics, serving as Chief Medical Officer. His position is noted alongside the restated direct ownership of 204,402 common shares in the amended Form 3/A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 07:20 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chin Peter Scott

(Last) (First) (Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BOULEVARD, SECOND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/10/2026

3. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
04/20/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	204,402(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 3/A is being filed to restate the Reporting Person's Table I ownership.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)